Idorsia

Idorsia has enrolled the first patients in the Dari‑Dream study, a randomized, placebo-controlled double-blind trial of about 344 adults and older participants over three months. The aim is to demonstrate that Quviviq improves not only nighttime sleep but also daytime functioning, so these data can be included in the US prescribing information. Results are expected in 2028; corresponding information is already included in the product information in several other countries. Quviviq is approved in the US and Europe for the treatment of sleep disorders. » Więcej na finanzen.net

In a randomized, placebo‑controlled phase‑2 study with 165 participants aged 10 to 17, a single dose of Daridorexant increased total sleep time by an average of 50 minutes, and by 64 minutes in children with neurodevelopmental disorders. Two‑week treatment was well tolerated; the safety profile and withdrawal symptoms were consistent with those seen in adults. Idorsia plans a phase‑3 study to start in the second half of next year. Daridorexant is already approved for adults as Quviviq in North America and Europe. » Więcej na finanzen.net

At the AHA congress, Idorsia presented further analyses from the Phase III Precision study showing rapid double-digit blood-pressure reductions in two hard-to-treat hypertension patient groups (obesity; combined heart, kidney and metabolic diseases). The data also point to a possible kidney-protective effect. Aprocitentan is approved in the US as Tryvio and in the EU, the UK, Switzerland and Canada as Jeraygo. » Więcej na finanzen.net